Regulus Therapeutics reported $2.89M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Astrazeneca AZN:US 3.06B 1.03B
AstraZeneca AZN:LN 3.06B 1.03B
Biogen BIIB:US $ 634.9M 153M
Celldex Therapeutics CLDX:US $ 6.91M 670K
Gilead Sciences GILD:US $ 1.08B 567M
GlaxoSmithKline GSK:LN 2.68B 227M
Intercept Pharmaceuticals ICPT:US $ 50.01M 10.58M
Intrexon XON:US $ 19.58M 2.81M
Lexicon Pharmaceuticals LXRX:US 8.49M 355K
Ligand Pharmaceuticals LGND:US $ 18.18M 444K
Merk MRK:US $ 2.3B 518M
Regulus Therapeutics RGLS:US $ 2.89M 339K
Sangamo Biosciences SGMO:US $ 14.91M 1.18M
Spectrum Pharmaceuticals SPPI:US $ 9.87M 9.02M
Takeda 4502:JP 223.43B 7.65B
Vital Therapies VTL:US $ 3.99M 647K
YTE INCY:US $ 209.58M 16.62M